Antileukinate

Modify Date: 2024-01-05 18:39:17

Antileukinate structure	Common Name	Antileukinate
	CAS Number	138559-60-1	Molecular Weight	1003.19000
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₄₅H₆₆N₁₈O₇S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Antileukinate

Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury[1][2][3].

Name	IL-8 Inhibitor
Synonym	More Synonyms

Description	Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury[1][2][3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> CXCR Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> CXCR
In Vitro	Antileukinate inhibits the binding of human eotaxin to human eosinophils with an IC50 of 8.2 μM[2]. Antileukinate (10 μM, 100 μM) significantly suppresses eosinophil chemotaxis to human eotaxin[2].
In Vivo	Antileukinate (52.63 mg/kg; s.c.) protectes mice against acute pancreatitis and associated lung injury[1]. Antileukinate (5mg/kg; s.c.) inhibits the interaction between murine eotaxin and murine eosinophil[2]. Animal Model: Swiss mice(20-25g)[1] Dosage: 52.63 mg/kg Administration: Subcutaneous injection Result: Reduced pancreatic edema induced by Caerulein (50 μg/kg).
References	[1]. Madhav Bhatia, et al. Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice against acute pancreatitis and associated lung injury. Regul Pept. 2007 Jan 10;138(1):40-8. [2]. Yuji Fukuno, et al. Chemokine receptor inhibitor, Antileukinate, suppressed ovalbumin-induced eosinophilic inflammation in the airway. Cytokine. 2003 Jun 7;22(5):116-25.